CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-17-00223
Health/Science/Disease Category:
Healthy Preterm Infants Needed
Purpose of Research:
To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session .
Short Name:
Full Title of Study:
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Phase/Type of Study:
Phase 2b Clinical Trial
Healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days
Time Commitment/Requirements:
Participation will last for 365 days (1 year); 7 visits will be performed.
Primary Investigator:
Dr. Pia Pannaraj
Coordinator Contact Name:
Melissa Lucero or Wesley Cheng
Phone Number:
323-361-2712 or 323-361-5811
Email: or
Clinical Trials .Gov Identifier: